{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T23:03:24Z","timestamp":1767827004834,"version":"3.49.0"},"reference-count":15,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Some patients with multiple myeloma are receiving treatment in clinical practice in England after prior exposure to a proteasome inhibitor, an immunomodulatory agent, and an anti\u2010CD38 monoclonal antibody. We investigated the characteristics of these patients, their outcomes, and the salvage therapies they received using the national cancer registry for England and linked healthcare data. After a median follow\u2010up time of 6.4 months from <jats:italic>T<\/jats:italic><jats:sub>0<\/jats:sub>, median overall survival and time to next treatment were 8.2 and 5.3 months, respectively. This real\u2010world data provide useful clinical insight into a little\u2010studied patient population and highlight the poor outcomes in the UK setting.<\/jats:p>","DOI":"10.1002\/jha2.214","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T23:05:12Z","timestamp":1623366312000},"page":"493-497","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A registry study of relapsed or refractory multiple myeloma pre\u2010exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38\u2010targeted monoclonal antibody therapy in England"],"prefix":"10.1002","volume":"2","author":[{"given":"Ahmed","family":"Elsada","sequence":"first","affiliation":[{"name":"Janssen UK  High Wycombe UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Zalin\u2010Miller","sequence":"additional","affiliation":[{"name":"Health Data Insight CIC  Cambridge UK"},{"name":"National Disease Registration Service Public Health England  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Knott","sequence":"additional","affiliation":[{"name":"Health Data Insight CIC  Cambridge UK"},{"name":"National Disease Registration Service Public Health England  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonidas","family":"Caravotas","sequence":"additional","affiliation":[{"name":"Janssen UK  High Wycombe UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"NICE. Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma. 2019.https:\/\/www.nice.org.uk\/guidance\/ta573."},{"key":"e_1_2_9_3_1","unstructured":"NICE. Daratumumab monotherapy for treating relapsed and refractory multiple myeloma. 2018.https:\/\/www.nice.org.uk\/guidance\/ta510."},{"key":"e_1_2_9_4_1","unstructured":"NICE. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma. 2020.https:\/\/www.nice.org.uk\/guidance\/ta658."},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.621"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"e_1_2_9_7_1","unstructured":"MehraM VogelM ValluriS NairS SchecterJ SlowikR et\u00a0al.Patient characteristics treatment patterns and outcomes in patients with triple\u2010class\u2010refractory multiple myeloma.25th EHA Annual Congress: European Hematology Association;2020."},{"key":"e_1_2_9_8_1","unstructured":"HoltM TaubeJ CarmichaelJ FeylerS CheesmanS LeeL et\u00a0al.Real\u2010world multi\u2010centre review of the effectiveness of dara monotherapy and patients\u2019 response to subsequent therapies.25th EHA Annual Congress: European Hematology Association;2020."},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17076"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz076"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyx015"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz137"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0104"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14213"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31240-1"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.214","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jha2.214","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.214","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:46:22Z","timestamp":1692751582000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1002\/jha2.214"],"URL":"https:\/\/doi.org\/10.1002\/jha2.214","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,10]]},"assertion":[{"value":"2021-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}